{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269525","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.662751+00:00","generated_at":"2026-05-16T23:39:52.187136+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO","bullets":["Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.","Net loss narrowed to $8.2M ($0.16 loss per share) from $11.1M loss in Q3 2024.","Raises FY2025 revenue guidance to $76-78M (from $72-76M); reduces adj. op. expense guidance to $90-92M.","Promoted Alison Bauerlein to COO from CFO, James Rodberg to CFO, effective Nov 5, 2025.","Board members Becker and Rogers resigned; board size reduced from 9 to 7."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269525","json":"https://secwatch.observer/filing/0001193125-25-269525.json","markdown":"https://secwatch.observer/filing/0001193125-25-269525.md","text":"https://secwatch.observer/filing/0001193125-25-269525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000119312525269525/0001193125-25-269525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000119312525269525/sght-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:39:52.187136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}